NILK-2301 / Light Chain Biosci, LamKap Bio - LARVOL DELTA

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Light Chain Bioscience - Novimmune SA

Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody. (PubMed, Front Immunol) - "Combination of a CEACAM5-targeting T-cell engager (NILK-2301) with NILK-2401 can either boost NILK-2301 activity (Emax) up to 2.5-fold or allows reaching equal NILK-2301 activity at >600-fold (LS174T) to >3,000-fold (MKN-45) lower doses. NILK-2401 combines promising preclinical activity with limited potential side effects due to the tumor-targeted blockade of CD47 and low immunogenicity and is planned to enter clinical testing."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CEACAM5 • SIRPA

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers (J Hematol Oncol) - "NILK-2301 alone or in combination with checkpoint inhibition showed activity in organotypic tumor tissue slices and colorectal cancer organoid models. In vivo, NILK-2301 at 10 mg/kg significantly delayed tumor progression in colon- and a pancreatic adenocarcinoma model."

Preclinical • Colorectal Cancer • Pancreatic Adenocarcinoma

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. (PubMed, J Hematol Oncol) - "In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023."

IO biomarker • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CEACAM5

"#LamKapBio presented data on #NILK2301 #NILK2401 and #NILK3301 https://t.co/rgAjaee38n" (@1stOncology)

Combination of κλ bispecific antibodies targeting innate (CEAxCD47, NILK-2401) and adaptive immunity (CEAxCD3, NILK-2301 and CEAxCD28, NILK-3301) for next generation immunotherapy of CEA-expressing cancers (AACR 2023) - "NILK-2301 and NILK-2401 are active as single agents. Addition of NILK-2401 or NILK-3301 to NILK-2301 significantly increases activity, already at 10 -100x lower CEAxCD3 doses. GMP drug substance has been produced for NILK-2301 and NILK-2401."

Gastric Cancer • Oncology • Solid Tumor • CD69 • CD8 • CEACAM5 • GZMB • IFNG • IL2RA • SIRPA

Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer (SITC 2022) - "Ethics Approval Animal experiments were approved by the animal research committee of Geneva canton and experiments performed in accordance with the Swiss Federal Veterinary Office guidelines. This included submission and approval of the project by the Commission Cantonale d'Expérimentation Animale (CCEA; GE83 and GE134)."

Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor • CEACAM5 • SIRPA

Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer (ESMO 2022) - "NILK-2301 + NILK-3301 combination treatment significantly increases activity already at low NILK-2301 doses with reduced cytokine release when given sequentially. IND-filing for NILK-2301 is expected in Q4/2022."

IO biomarker • Gastric Cancer • Oncology • CD4 • CD8 • CEACAM5 • IFNG • IL2 • IL2RA • IL6 • TNFA

LamKap Bio beta to present data on NILK-2401 & NILK-2301 (LamKap Bio Press Release) - "LamKap Bio beta to present data on NILK-2401 ± NILK-2301 programs SITC 37th Annual Meeting 2022. The SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) will host the 37th Annual Meeting & Pre-Conference Programs November 8-12, 2022. LamKap Bio beta is very pleased to present for the first time preclinical data on the development of NILK-2401 (CEAxCD47) ± NILK-2301 (CEAxCD28) bispecific antibodies for immunotherapy of patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) expressing solid tumors."

Preclinical • Oncology • Solid Tumor

"#LamKap Bio beta to present data on #NILK2401 & #NILK2301 at #SITC22 https://t.co/ARtrhDKYdK" (@1stOncology)

Oncology